Newly Published Journal of Antimicrobial Chemotherapy Supplement Provides Insights into the Future of Echinocandin Therapy fo...
January 04 2018 - 8:00AM
Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced that a new compendium of papers published as a Journal of
Antimicrobial Chemotherapy supplement reviews evidence and provides
insights into the future of echinocandin therapy, including
strategies for the treatment and prevention of life-threatening
invasive fungal infections.
“Fungal infections are an important cause of morbidity and
mortality worldwide, in particular among the expanding population
of immunosuppressed and elderly patients, prompting a serious
review of our current therapeutic approaches and the development of
new options,” said Matteo Bassetti, M.D., guest editor of Journal
of Antimicrobial Chemotherapy and head of the Infectious Diseases
Division of the Santa Maria Misericordia University Hospital,
Udine, Italy. “This newly published compendium of papers presents
perspectives on how the current use of echinocandin antifungals can
be improved and how newer options would augment treatment and
prophylaxis strategies in the future, especially in a world of
increasing patient complexity.”
The supplement, titled “The Future of Echinocandin Therapy," can
be downloaded here. It is comprised of nine papers authored by Dr.
Bassetti and other experts from Europe and North America who worked
independently to review the latest evidence and examine the latest
in practice and research, leading echinocandins into the future of
antifungal treatment and prophylaxis. The authors selected and
covered the most critical aspects facing them in clinical practice
and research, including: antifungal drug safety and toxicities,
pharmacokinetics, novel antifungal agents in development, and
therapy and prevention among a complex and diverse patient
population (including patients in the ICU, patients with cancer,
and patients undergoing transplant).
About Invasive Fungal Infections
Fungal infections can carry a mortality rate of 35-50 percent,
higher than most bacterial infections. Approximately 97,000
Americans die from hospital-related fungal infections each year and
90 percent of these infections are caused by two common fungi,
Candida and Aspergillus. These infections represent a significant
public health issue, particularly in highly vulnerable patient
populations at risk for infection, such as the elderly,
post-surgical, critically ill and other hospitalized patients with
serious medical conditions. There is an urgent and growing need for
new therapeutic approaches to treat and prevent serious invasive
fungal infections.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on
developing new anti-infectives that have the potential to transform
the standard of care and save or improve patients’ lives. The
company is currently advancing its novel echinocandin antifungal,
rezafungin acetate, formerly called CD101 IV, through Phase 2 and
developing CD201, its bispecific antibiotic immunotherapy, for the
treatment of multi-drug resistant Gram-negative bacterial
infections. Rezafungin has improved pharmacokinetics compared to
existing echinocandins and has the potential for expanded utility
across patient settings. Rezafungin is the only once-weekly product
candidate in development for the treatment and prevention of
life-threatening invasive fungal infections. CD201 is the first
drug candidate selected from Cidara’s novel Cloudbreak™ platform,
the first immunotherapy discovery platform designed specifically to
create compounds that directly kill pathogens and also direct a
patient’s immune cells to attack and eliminate bacterial, fungal or
viral pathogens. Cidara has received a grant for up to $6.9 million
from CARB-X (Combating Antibiotic Resistant Bacteria Accelerator)
to advance the development of CD201 and back-up molecules. Cidara
is headquartered in San Diego, California. For more information,
please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the anticipated timing of topline data for the STRIVE trial, the
effectiveness, safety, and other attributes of rezafungin and other
potential product candidates, including the potential for these
compounds to successfully treat or prevent infections, including
those caused by resistant pathogens, and augment treatment and
prophylaxis strategies in the future, the design and timing of
rezafungin Phase 3 clinical trials, the potential for CD201 to
successfully treat or prevent infections and the potential for the
Cloudbreak platform to result in future drug candidates. Risks that
contribute to the uncertain nature of the forward-looking
statements include: the success and timing of Cidara’s preclinical
studies and clinical trials; regulatory developments in the United
States and foreign countries; changes in Cidara’s plans to develop
and commercialize its product candidates; Cidara’s ability to
obtain additional financing; Cidara’s ability to obtain and
maintain intellectual property protection for its product
candidates; and the loss of key scientific or management personnel.
These and other risks and uncertainties are described more fully in
Cidara’s Form 10-Q most recently filed with the United States
Securities and Exchange Commission. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Cidara undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
INVESTOR CONTACT:Robert H. UhlWestwicke
Partners, LLCManaging Director(858)
356-5932robert.uhl@westwicke.com
MEDIA CONTACT:Christy Curran Sam Brown
Inc.615-414-8668ChristyCurran@sambrown.com
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Oct 2023 to Oct 2024